News
27.5.21

Innosuisse innovation project starting May 2021

We are pleased to announce that TOPADUR Pharma in collaboration with the University Hospital of Zurich and the University of Zurich has received CHF 859k funding by Innosuisse. We are happy to work together with Prof. Scharl and Prof. Pruschy and their teams to develop an innovative drug for the prevention and treatment of colorectal cancer. The project entitled “Translational IND enabling studies to develop an innovative drug candidate, TOP-V122 for the treatment and prevention of colorectal cancer” will bring together a powerful and effective small molecule drug discovery & development from the biotech start-up company TOPADUR Pharma  together with world leader academic experts in CRC. It is intended to better understand the tumor response at the ex-vivo and in-vivo levels of our novel pharmacological agent alone or in combination with classical chemotherapy and /or ionizing radiation. A major goal is to understand treatment mechanisms and to translate these novel combined treatment modalities into a clinical environment. We believe that this drug candidate has a huge potential to treat and prevent such a devastating disease like colorectal cancer resulting in improved patients care.

Download DocumentDokument herunterladen
8.10.20
News

Interview with Reto Naef, CEO of TOPADUR PHARMA AG

The Switzerland Global Enterprise interviewed Reto Naef, CEO of TOPADUR PHARMA AG.

Read more
10.11.20
Press Release

TOPADUR announces positive results from an interim analysis of Phase I trial

TOPADUR announces positive results from an interim analysis of Phase I clinical trial with their new wound healing drug candidate.

Read more
6.7.21
Press Release

TOPADUR Pharma AG announces completion of TOP-N53 First-in-Man Study

TOPADUR announces the completion of Phase 1 dose escalation study of TOP-N53, a first-in-class wound healing drug candidate.

Read more